Spot-Fixing Scandal
Scandal engulfs Indian cricket; web of players, bookies faces scrutiny
Cricket, the "gentleman's game", has been hit by a series of gambling-related scandals in international matches in recent years. But S.Sreesanth's case is the first time allegations of "fixing" in the IPL are being heard in a court of law, despite a huge, illegal betting industry that has grown up around the tournament. Full Article
REUTERS SHOWCASE
 |
Deflated expectations
Breakingviews columnists discuss the implications of inflation being in decline globally. Video
Revenge of Markets
For months, markets have been dancing to central bankers' tune, but that may now be changing, writes James Saft. Full Article
Buy, Sell or Hold?
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
Cipla Q3 net up 25.5 percent, slightly misses estimates
A pharmacist gives medicine inside a government hospital in Kolkata July 3, 2012.
Credit: Reuters/Rupak De Chowdhuri
MUMBAI |
MUMBAI (Reuters) - Cipla Ltd (CIPL.NS), India's fifth largest drugmaker by sales, reported a 25.5 percent rise in quarterly profit on robust sales but slightly missed street estimates as taxes surged.
The Mumbai-based drugmaker said, net profit grew to 3.39 billion rupees in October-December from 2.7 billion rupees a year earlier. Analysts on an average had expected a net profit of 3.48 billion rupees, according to Thomson Reuters I/B/E/S.
Sales rose 18.65 percent to 20.3 billion rupees, it said.
Shares in Cipla fell 0.56 percent to 405 rupees on Wednesday when the Mumbai market closed down 0.1 percent. (Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters